Solara Q4 Revenue Up 40% YoY, PAT at INR 96mn

Solara reported Q4 FY26 overall revenue growth of 40% YoY to INR 3,919mn, with PAT of INR 96mn, marking its highest revenue and EBITDA in eight quarters.
The base API business excluding Ibuprofen grew 36% YoY with strong margins (54% GM, 26% EBITDA), while the commodity Ibuprofen business reported negative EBITDA of INR -179mn.
Management has appointed bankers to evaluate strategic options for the struggling Ibuprofen business, putting the planned carve-out of polymers and CRAMS on hold.
Net debt reduced to INR 6,141mn as of Mar'26, with a further reduction to ~INR 5,030mn expected by May'26 after rights issue proceeds application.